Characterization of Enzymatic Biomarkers in Salivary Samples for Early Detection of Pancreatic in Kirkuk

Israa Rafi Jamal; Lolawa J. Falah

doi:10.51699/cajotas.v7i4.1737

Authors

Israa Rafi Jamal Salah Al-Din Education Directorate, Tikrit Education Department, Iraq
Lolawa J. Falah Salah Al-Din Education Directorate, Tikrit Education Department, Iraq

DOI:

https://doi.org/10.51699/cajotas.v7i4.1737

Keywords:

Pancreatic Cancer, Salivary Biomarkers, Proteomics, Enzymatic Biomarkers, MMP-9, Non-Invasive Diagnostics, LC-MS/MS

Abstract

Pancreatic cancer is one of the most aggressive malignancies, with a high mortality rate due to late-stage diagnosis and the absence of reliable early detection methods. Current diagnostic approaches, such as imaging and serum biomarkers (e.g., CA 19-9), are often invasive, expensive, and lack sufficient sensitivity and specificity. Saliva has emerged as a promising biofluid for non-invasive diagnostics, offering a unique window into systemic diseases, including cancer. This study aims to explore the potential of enzymatic biomarkers in saliva for the early detection of pancreatic cancer using a proteomic approach. This study investigates the differential expression of salivary enzymatic biomarkers in pancreatic cancer patients compared to healthy controls. The primary objective is to characterize and validate key enzymatic proteins that could serve as reliable, non-invasive diagnostic indicators for early pancreatic cancer detection. A case-control study was conducted on 100 participants (50 pancreatic cancer patients and 50 healthy controls). Unstimulated whole saliva samples were collected, processed, and analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS) to identify differentially expressed enzymes. Western blot and ELISA were used for biomarker validation. Statistical tests, including ROC curve, AUC, sensitivity, and specificity analysis, were performed to measure biomarker performance. Proteomic profiling revealed a significant upregulation of MMP-9, LDH, Amylase, and ALP in pancreatic cancer patients compared to healthy controls (p < 0.001). MMP-9 had the optimal diagnostic performance (AUC = 0.91, sensitivity = 89.5%, specificity = 92.1%), followed by LDH (AUC = 0.88, sensitivity = 85.2%, specificity = 88.7%). Pathway analysis linked these enzymes with extracellular matrix remodeling, inflammation, and dysregulation of metabolism, which are of crucial significance in pancreatic cancer development. The current study demonstrates that salivary enzymatic biomarkers possess vast potential as a non-invasive diagnostic tool for the early diagnosis of pancreatic cancer. The greater sensitivity and specificity of MMP-9 and LDH suggest their potential application in clinical screening programs, particularly in cases involving population at high risk. Large-scale studies need to be conducted to validate these findings and render them clinically useful.

Downloads

Download data is not yet available.

References

Z. Zhao and W. Liu, “Pancreatic cancer: A review of risk factors, diagnosis, and treatment,” Technology in Cancer Research & Treatment, vol. 19, Art. no. 1533033820962117, 2020.

A. Singh, “Global burden of five major types of gastrointestinal cancer,” Gastroenterology Review / Przegląd Gastroenterologiczny, vol. 19, no. 1, 2024.

T. E. Clancy, “Surgery for pancreatic cancer,” Hematology/Oncology Clinics, vol. 29, no. 4, pp. 701–716, 2015.

M. S. Petrov and D. Yadav, “Global epidemiology and holistic prevention of pancreatitis,” Nature Reviews Gastroenterology & Hepatology, vol. 16, no. 3, pp. 175–184, 2019.

H. Zhu, T. Li, Y. Du, and M. Li, “Pancreatic cancer: challenges and opportunities,” BMC Medicine, vol. 16, no. 1, Art. no. 214, 2018.

W. James, “Gastrointestinal pathologies, dysfunctions, and disorders,” in Mosby’s Pathology for Massage Professionals-E-Book. Netherlands: Elsevier Health Sciences, p. 306, 2021.

S. Das, M. K. Dey, R. Devireddy, and M. R. Gartia, “Biomarkers in cancer detection, diagnosis, and prognosis,” Sensors, vol. 24, no. 1, Art. no. 37, 2023.

W. S. Tummers, J. K. Willmann, B. A. Bonsing, A. L. Vahrmeijer, S. S. Gambhir, and R.-J. Swijnenburg, “Advances in diagnostic and intraoperative molecular imaging of pancreatic cancer,” Pancreas, vol. 47, no. 6, pp. 675–689, 2018.

K. P. Farr, D. Moses, K. S. Haghighi, P. A. Phillips, C. M. Hillenbrand, and B. H. Chua, “Imaging modalities for early detection of pancreatic cancer: Current state and future research opportunities,” Cancers, vol. 14, no. 10, Art. no. 2539, 2022.

D. T. H. De Moura, M. Ryou, E. G. H. De Moura, I. B. Ribeiro, W. M. Bernardo, and C. C. Thompson, “Endoscopic ultrasound-guided fine needle aspiration and endoscopic retrograde cholangiopancreatography-based tissue sampling in suspected malignant biliary strictures: A meta-analysis of same-session procedures,” Clinical Endoscopy, vol. 53, no. 4, pp. 417–428, 2020.

T. Lee, T. Z. J. Teng, and V. G. Shelat, “Carbohydrate antigen 19-9—Tumor marker: Past, present, and future,” World Journal of Gastrointestinal Surgery, vol. 12, no. 12, pp. 468–490, 2020.

S. Scarà, P. Bottoni, and R. Scatena, “CA 19-9: Biochemical and clinical aspects,” in Advances in Cancer Biomarkers: From Biochemistry to Clinic for a Critical Revision, pp. 247–260, 2015.

A. V. Özdemir, Clinical Use of Tumor Markers.

M. El Bouhairi, O. Lachhab, and M. Sidqui, “Advancements in salivary biomarkers: Transforming diagnostic landscape in dentistry,” American Journal of Innovative Research and Applied Sciences, pp. 12–19, 2024.

Y. Cui, M. Yang, J. Zhu, H. Zhang, Z. Duan, S. Wang, et al., “Developments in diagnostic applications of saliva in human organ diseases,” Medicine in Novel Technology and Devices, vol. 13, Art. no. 100115, 2022.

R. Goldoni, Design and Development of a Point-of-Care Device for Oral Health Assessment via Salivary Diagnostics, 2024.

M. S. Petrov and D. Yadav, “Global epidemiology and holistic prevention of pancreatitis,” Nature Reviews Gastroenterology & Hepatology, vol. 16, no. 3, pp. 175–184, 2019.

L. A. Soares Nunes, S. Mussavira, and O. Sukumaran Bindhu, “Clinical and diagnostic utility of saliva as a non-invasive diagnostic fluid: A systematic review,” Biochemia Medica, vol. 25, no. 2, pp. 177–192, 2015.

F. Papale, S. Santonocito, A. Polizzi, A. L. Giudice, S. Capodiferro, G. Favia, and G. Isola, “The new era of salivaomics in dentistry: Frontiers and facts in the early diagnosis and prevention of oral diseases and cancer,” Metabolites, vol. 12, no. 7, Art. no. 638, 2022.

K. E. A. Alkasah, Can Salivary EVs Be Used as Diagnostic Biomarkers in Oral Squamous Cell Carcinoma?, Ph.D. dissertation, The University of Sheffield, Sheffield, U.K., 2022.

K. Dhama, S. K. Latheef, M. Dadar, H. A. Samad, A. Munjal, R. Khandia, et al., “Biomarkers in stress related diseases/disorders: Diagnostic, prognostic, and therapeutic values,” Frontiers in Molecular Biosciences, vol. 6, Art. no. 91, 2019.

M. Cristaldi, R. Mauceri, O. Di Fede, G. Giuliana, G. Campisi, and V. Panzarella, “Salivary biomarkers for oral squamous cell carcinoma diagnosis and follow-up: Current status and perspectives,” Frontiers in Physiology, vol. 10, Art. no. 1476, 2019.

N. Ghosh, M. Dutta, B. Singh, R. Banerjee, P. Bhattacharyya, and K. Chaudhury, “Transcriptomics, proteomics and metabolomics driven biomarker discovery in COPD: An update,” Expert Review of Molecular Diagnostics, vol. 16, no. 8, pp. 897–913, 2016.

K. E. Kaczor-Urbanowicz, C. Martin Carreras-Presas, K. Aro, M. Tu, F. Garcia-Godoy, and D. T. Wong, “Saliva diagnostics—Current views and directions,” Experimental Biology and Medicine, vol. 242, no. 5, pp. 459–472, 2017.

M. Koopaie, S. Kolahdooz, M. Fatahzadeh, and Z. A. Aleedawi, “Salivary noncoding RNA in the diagnosis of pancreatic cancer: Systematic review and meta-analysis,” European Journal of Clinical Investigation, vol. 52, no. 12, Art. no. e13848, 2022.

M. Gonzalez Agurto, N. Olivares, G. Canedo-Marroquin, D. Espinoza, and S. C. Tortora, “The intersection of the oral microbiome and salivary metabolites in head and neck cancer: From diagnosis to treatment,” Cancers, vol. 16, no. 20, Art. no. 3545, 2024.

C. Liao, X. Chen, and Y. Fu, “Salivary analysis: An emerging paradigm for non-invasive healthcare diagnosis and monitoring,” Interdisciplinary Medicine, vol. 1, no. 3, Art. no. e20230009, 2023.

S. Bellando-Randone, E. Russo, V. Venerito, M. Matucci-Cerinic, F. Iannone, S. Tangaro, and A. Amedei, “Exploring the oral microbiome in rheumatic diseases, state of the art and future prospective in personalized medicine with an AI approach,” Journal of Personalized Medicine, vol. 11, no. 7, Art. no. 625, 2021.

E. S. Nakayasu, M. Gritsenko, P. D. Piehowski, Y. Gao, D. J. Orton, A. A. Schepmoes, et al., “Tutorial: Best practices and considerations for mass-spectrometry-based protein biomarker discovery and validation,” Nature Protocols, vol. 16, no. 8, pp. 3737–3760, 2021.

J. Liu, D. Huang, Y. Cai, Z. Cao, Z. Liu, S. Zhang, et al., “Saliva diagnostics: Emerging techniques and biomarkers for salivaomics in cancer detection,” Expert Review of Molecular Diagnostics, vol. 22, no. 12, pp. 1077–1097, 2022.

R. M. Sallam, “Proteomics in cancer biomarkers discovery: Challenges and applications,” Disease Markers, vol. 2015, Art. no. 321370, 2015.

G. Weng, J. Tao, Y. Liu, J. Qiu, D. Su, R. Wang, et al., “Organoid: Bridging the gap between basic research and clinical practice,” Cancer Letters, vol. 572, Art. no. 216353, 2023.

P. Huang, W. Gao, C. Fu, and R. Tian, “Functional and clinical proteomic exploration of pancreatic cancer,” Molecular & Cellular Proteomics, vol. 22, no. 7, Art. no. 100575, 2023.

Z. Piperigkou, K. Kyriakopoulou, C. Koutsakis, S. Mastronikolis, and N. K. Karamanos, “Key matrix remodeling enzymes: Functions and targeting in cancer,” Cancers, vol. 13, no. 6, Art. no. 1441, 2021.

X. Huang, Y. Lan, E. Li, J. Li, Q. Deng, and X. Deng, “Diagnostic values of MMP-7, MMP-9, MMP-11, TIMP-1, TIMP-2, CEA, and CA19-9 in patients with colorectal cancer,” Journal of International Medical Research, vol. 49, no. 5, Art. no. 03000605211012570, 2021.

S. Rafaqat, R. Hafeez, R. Mairaj, A. Saleem, and S. Rafaqat, “Pancreatic biomarkers: Role in diabetes mellitus,” Journal of Pancreatology, vol. 6, no. 4, pp. 169–177, 2023.

C. Tiffon, “Defining parallels between the salivary glands and pancreas to better understand pancreatic carcinogenesis,” Biomedicines, vol. 8, no. 6, Art. no. 178, 2020.

K. G. de la Cruz-López, L. J. Castro-Muñoz, D. O. Reyes-Hernández, A. García-Carrancá, and J. Manzo-Merino, “Lactate in the regulation of tumor microenvironment and therapeutic approaches,” Frontiers in Oncology, vol. 9, Art. no. 1143, 2019.

N. Evalde, P. O. James, O. Onuorah, C. C. Ilo, D. Okeowhor, S. Cosmas, and O. A. Durojaye, “Clinical diagnosis of disease states using enzymes and proteins,” Asian Journal of Biochemistry, Genetics and Molecular Biology, vol. 1, pp. 1–6, 2018.

F. V. Winck, A. C. Prado Ribeiro, R. Ramos Domingues, L. Y. Ling, D. M. Riaño-Pachón, C. Rivera, et al., “Insights into immune responses in oral cancer through proteomic analysis of saliva and salivary extracellular vesicles,” Scientific Reports, vol. 5, no. 1, Art. no. 16305, 2015.

P. Ahmad, A. Hussain, and W. L. Siqueira, “Mass spectrometry-based proteomic approaches for salivary protein biomarkers discovery and dental caries diagnosis: A critical review,” Mass Spectrometry Reviews, vol. 43, no. 4, pp. 826–856, 2024.

T. T. Ogunjobi, P. N. Ohaeri, O. T. Akintola, D. O. Atanda, F. P. Orji, J. O. Adebayo, et al., “Bioinformatics applications in chronic diseases: A comprehensive review of genomic, transcriptomics, proteomic, metabolomics, and machine learning approaches,” Medinformatics, 2024.

A. Punetha and D. Kotiya, “Advancements in oncoproteomics technologies: Treading toward translation into clinical practice,” Proteomes, vol. 11, no. 1, Art. no. 2, 2023.

K. Waury, E. A. Willemse, E. Vanmechelen, H. Zetterberg, C. E. Teunissen, and S. Abeln, “Bioinformatics tools and data resources for assay development of fluid protein biomarkers,” Biomarker Research, vol. 10, no. 1, Art. no. 83, 2022.

W. Jelski and B. Mroczko, “Biochemical diagnostics of pancreatic cancer—Present and future,” Clinica Chimica Acta, vol. 498, pp. 47–51, 2019.

H. Al Balushi, P. Chowdhury, H. M. Babu, A. Rehman, S. F. H. Bokhari, L. M. Al-Tarawneh, et al., “The potential of salivary biomarkers in early detection of pancreatic ductal adenocarcinoma: A systematic review,” Cureus, vol. 16, no. 2, 2024.

K. Nijakowski, J. Zdrojewski, M. Nowak, D. Gruszczyński, F. Knoll, and A. Surdacka, “Salivary metabolomics for systemic cancer diagnosis: A systematic review,” Metabolites, vol. 13, Art. no. 28, 2023.

M. Humeau, A. Vignolle-Vidoni, F. Sicard, F. Martins, B. Bournet, L. Buscail, et al., “Salivary microRNA in pancreatic cancer patients,” PLoS One, vol. 10, no. 6, Art. no. e0130996, 2015.

W. Zhao, M. Song, J. Zhang, M. Kuerban, and H. Wang, “Combined identification of long non-coding RNA CCAT1 and HOTAIR in serum as an effective screening for colorectal carcinoma,” International Journal of Clinical and Experimental Pathology, vol. 8, no. 11, pp. 14131–14140, 2015.